GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
In September 2026, 37.5% of US weekly GLP-1 injection users (75 of 200, n=200) said they would be likely to switch to a once-daily pill at the same monthly price and the same weight loss, falling to 17.0% if the pill gave about 12% weight loss instead of about 15%.
- Who was asked
- US weekly GLP-1 injection users, 200 clones, US
- When
- September 2026 (fielded 27 September 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- Instead of asking whether people prefer pills or injections in general, the study asked current weekly injectors to rate switching three times, changing one thing each time: nothing, a three-point weight-loss gap, and a strict morning dosing rule.
Section 01: What the panel said
- #
37.5%
37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to.
base 200
- #
17%
A pill giving about 12% weight loss instead of about 15% cuts the share likely to switch to 17.0% (34 of 200); 42 of the 75 parity switchers drop out.
base 200 · contrast
- #
27%
A strict empty-stomach morning rule costs fewer switchers: 27.0% (54 of 200) remain likely, and 46 of the 47 who were very likely at parity still lean to the pill.
base 200 · contrast
- #
17
Only 18 of 200 put avoiding the needle first, but 17 of those 18 would switch at parity and 15 of 18 even with the smaller weight loss.
base 18 · Put avoiding the needle first · caveat
37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to.
02Is a GLP-1 pill a like-for-like replacement for the weekly injection?
Not for most people who already inject. With the price and the weight loss held exactly equal, 37.5% of weekly injection users (75 of 200) said they would be likely to switch to a once-daily pill, and 55.0% (110 of 200) said they would be very unlikely to. The people who are settled on a weekly routine mostly see a daily pill as one more thing to remember, not as a relief.
So the pill does have a market among current injectors, but it is a minority one, and it depends on the pill giving up nothing.
03Which trade-off costs the pill more switchers, weaker results or a stricter routine?
Weaker results, by a clear margin. A pill giving about 12% weight loss instead of about 15% cut the share likely to switch to 17.0% (34 of 200), and 42 of the 75 who would have switched at parity dropped out. A strict morning rule, taken on an empty stomach with nothing to eat or drink for 30 minutes, cut it to 27.0% (54 of 200).
The morning rule barely touched the most committed: 46 of the 47 who were very likely to switch at parity still leaned to the pill under it, against 30 of 47 once the weight loss slipped.
04Who is the pill really for?
The more interesting read is that the pill's demand is two different groups. The first is small and firm: only 18 of 200 put avoiding the needle first, but 17 of those 18 would switch at parity and 15 of 18 would still switch with the smaller weight loss. The second is larger and conditional: of the 72 who put weight loss first, 30 would switch at parity and only 8 once the pill worked less well.
Almost nobody who valued the once-a-week dose would move: 1 of 18 at parity. For them the injection is the convenient option.
05What would a brand or access team do with this?
- A reading, not the panel's answer: lead oral messaging with results matching the injection, because weight loss (36.0%) and monthly cost (33.5%) outrank not using a needle (9.0%) as the thing that matters most.
- Treat needle aversion as the reliable niche, small but tolerant of trade-offs, and treat everyone else as switchable only on equal outcomes.
- Explain dosing rules plainly rather than hide them: they cost fewer switchers than an efficacy gap does.
Section 06: What they said, and the interview line it rests on
“I would be a 5 - Very likely, without a doubt. I've literally already tried switching to a pill—I asked my doctor to prescribe it, but my insurance denied it because it was only name brand and didn't have a generic yet. Injections are a huge pain. The pens take up room in the fridge, it's scary when your kids see you shooting yourself with a needle, and people immediately think you have diabetes. Even when the interviewer told me the pill is something you have to take every day instead of once a week, I said right away that I'd still switch from the syringe. If it gives the exact same weight loss and costs the same, getting rid of the needles is a total no-brainer for me.”
Predicted from this line in the interview
“I'll still switch the pill versus the syringe. That's a lot easier to I could take it anywhere anytime.”
“I would be very unlikely to switch. I've actually thought about this before, and I honestly prefer taking a once-a-week injection over dealing with a daily pill. Doing my injection once a week is simple, and taking a pill every single day would just be a hassle. If it were a weekly pill, maybe I'd consider it, but if it costs the exact same and gives the same results, the only thing that would really tempt me to switch medications is a lower price point. Since it's the same cost and same efficacy, I'm sticking with my weekly injection.”
Predicted from this line in the interview
“I think that I almost prefer a once a week injection over a daily pill.”
“I'd be very unlikely to switch. Even though I'm terrified of needles and literally have to go to my mom's house once a week to let her inject me, I'd still rather suck it up and do the weekly shot than take a daily pill. For one, I'm pretty forgetful, so having to remember to take something every single morning sounds like a hassle. But more importantly, if it's less effective, there's no way. I'm taking this purely for weight loss, and for me to ever consider switching medications, it would have to offer more extreme results, not less.”
Predicted from this line in the interview
“I know some people who were on the pill version of it and they said it's nowhere near as effective. So, I would rather suck it up and do the needle than take a pill every day.”
Section 07: How much should you trust this?
What we would defend
- Roughly a third of weekly injectors lean to a pill at equal price and results (75 of 200), stable across three independent reads of the study.
- A modest efficacy gap costs the pill more switchers than a strict morning dosing rule does (34 versus 54 of 200 still likely), and the ladder is internally consistent: only 1 of 125 non-switchers at parity became likely under either trade-off.
What we would not
- The exact size of the very unlikely group (55.0%, n=200): the answers are polarised and the clones may overstate firm refusal.
- Age differences: 71 of 200 have no age recorded, so the sharper drop among 30-44 year olds (21 to 5 of 48) is direction only.
- The needle-first group as a market size: 18 clones, reported as counts.
The main limitation
The panel is 200 clones of US weekly GLP-1 injection users; some pay for compounded injections, so an equal monthly price means different money to different people, and the 12% and 15% figures are illustrative, not any product's label.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Women | 96 |
| Men | 33 |
| Another gender | 1 |
| Gender not recorded | 70 |
Question wording as fielded
- Which best describes your use of a GLP-1 medicine (for weight loss or type 2 diabetes)? / I currently take a weekly injection / I currently take a daily pill / I used one before but have stopped / I have never taken one
- If a once-daily GLP-1 pill cost exactly the same each month as your weekly GLP-1 injection and gave the same weight loss, how likely would you be to switch from the injection to the pill? 1 to 5, where 1 is very unlikely and 5 is very likely.
- If a once-daily GLP-1 pill cost exactly the same each month as your weekly GLP-1 injection but gave slightly less weight loss (about 12% of body weight instead of about 15%), how likely would you be to switch from the injection to the pill? 1 to 5, where 1 is very unlikely and 5 is very likely.
- If a once-daily GLP-1 pill cost exactly the same each month as your weekly GLP-1 injection and gave the same weight loss, but had to be swallowed each morning on an empty stomach with a sip of water and then no food or drink for 30 minutes, how likely would you be to switch from the injection to the pill? 1 to 5, where 1 is very unlikely and 5 is very likely.
- When choosing between a weekly GLP-1 injection and a once-daily GLP-1 pill, which one thing matters most to you? / How much weight I lose / Not having to use a needle / Only having to remember a dose once a week / Side effects such as nausea / What I pay each month
What was not asked, and why
No manufacturer, brand or product was named, and no price point was set: every scenario held the monthly cost equal so that only results or routine changed. Current pill users and past users were screened out.
What changed from the obvious question
Instead of asking whether people prefer pills or injections in general, the study asked current weekly injectors to rate switching three times, changing one thing each time: nothing, a three-point weight-loss gap, and a strict morning dosing rule.
Fielded through Ask Brox on 27 September 2026.
More on GLP-1: starting, stopping and restarting · Pharma & HCP · GLP-1 (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
67.5% 67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. (base 166)
Read -
When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
65.5% 65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. (base 139)
Read -
Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
35.3% 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage (base 170)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read